Tissue Dynamics

Sensor Illuminated Drug Discovery

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in January 2017 by Yaakov Nahmias, Tissue Dynamics operates with 11–50 employees. The company has raised $3.26M across two funding rounds. In February 2024, Tissue Dynamics announced a strategic collaboration with ATCC to bring a transformative heart organoid model to market.

Business overview

Tissue Dynamics is a biotechnology company focused on transforming drug and cosmetic development through next-generation organ-on-chip (OOC) tools. The company's bionic OOC platform provides sensor-integrated organ tissues that emulate human physiology, offering real-time monitoring and data analysis using smart algorithms. This technology aims to increase clinical success rates, accelerate drug development, and reduce research and development costs for the pharmaceutical, nutraceutical, and cosmetic industries. Tissue Dynamics operates within the Health Tech & Life Sciences sector, specifically targeting Drugs Discovery & Development.

Strategic signal

In May 2026, Tissue Dynamics and Galmed Pharmaceuticals announced a collaboration to develop a human-centered chronic cardiac fibrosis platform. This partnership is significant as it aims to advance Aramchol-based therapeutics, indicating a strategic move towards addressing specific disease areas and validating Tissue Dynamics' OOC technology for complex therapeutic development.

Company Intelligence Q&A

What was the most recent strategic collaboration for Tissue Dynamics?
In May 2026, Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. announced a collaboration to develop a human-centered chronic cardiac fibrosis platform, aiming to advance Aramchol-based therapeutics.
What was the nature of the collaboration between Tissue Dynamics and ATCC?
In February 2024, ATCC and Tissue Dynamics announced a strategic collaboration focused on bringing a transformative heart organoid model to market.
What was the focus of the collaboration between Tissue Dynamics and Galmed Pharmaceuticals in June 2026?
In June 2026, Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. unveiled an unknown metabolic pathway for cardiac fibrosis and heart failure, which supports the development of Aramchol for cardiac fibrosis.
When was Tissue Dynamics founded and by whom?
Tissue Dynamics was founded in January 2017 by Yaakov Nahmias.

External links